The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 778K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

21 articles for Y An


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
8
Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors.EBI
Sookmyung Women'S University
45
Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).EBI
Bristol Myers Squibb
17
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.EBI
Bristol Myers Squibb
37
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.EBI
Bristol Myers Squibb
19
Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.EBI
Bristol Myers Squibb
24
Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation.EBI
Bristol Myers Squibb
25
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).EBI
Bristol Myers Squibb
19
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.EBI
Bristol Myers Squibb
36
Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase.EBI
Bristol Myers Squibb
27
Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer.EBI
Sun Yat-Sen University
4
Construction and activity evaluation of novel benzodioxane derivatives as dual-target antifungal inhibitors.EBI
Liaocheng University
5
Design, Synthesis, and Biological Evaluation of Dual-Target COX-2/CYP51 Inhibitors for the Treatment of Fungal Infectious Diseases.EBI
Liaocheng University
14
Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.EBI
Bristol Myers Squibb
3
Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure.EBI
Liaocheng University
3
Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.EBI
Liaocheng University
35
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.EBI
Bristol Myers Squibb
19
Optimization and biological evaluation of 2-aminobenzothiazole derivatives as Aurora B kinase inhibitors.EBI
Sookmyung Women'S University
98
Heterocyclic compounds, process for preparation of the same and use thereofBDB
Shanghai Institute of Material Medica, Chinese Academy of Sciences
53
Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2BDB
Effector Therapeutics
4
Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.BDB
Lawrence Berkeley National Laboratory
18
Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.BDB
Schering-Plough Research Institute